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Abstract. Programmed cell death ligand 1 (PD-L1) expressed 
in cancer cells interacting with its receptor programmed cell 
death 1 (PD-1) expressed in immune cells represents a regula-
tory axis linked to the suppression and evasion of host immune 
functions. The blockade of PD-1/PD-L1 interaction using 
monoclonal antibodies has emerged as an effective therapy 
for several solid tumors; however, durable response has been 
observed in a subset of patients with PD-L1-positive tumors. 
Thus, the understanding of the mechanisms responsible for 
the expression of PD-L1 in tumor cells may help to improve 
the response to PD-L1 blockade therapies. In this study, we 
investigated whether resveratrol, a grape-derived stilbenoid 
with immunoregulatory activity, modulates the expression 
of PD-L1 in breast and colorectal cancer cells. The surface 
expression of PD‑L1 was determined by flow cytometry in 
cancer cells treated with resveratrol and/or piceatannol. Each 
stilbenoid alone induced PD-L1 and when used in combina-
tion, elicited a synergistic upregulation of PD-L1 in some 
cell lines. The induction of PD-L1 by the combined use of 
stilbenoids was most pronounced in the Cal51 triple-negative 
breast cancer (TNBC) and SW620 colon cancer cells. The 
observed induction of PD-L1 was transcriptionally medi-
ated by nuclear factor (NF)-κB, as shown by NF-κB reporter 
assays, the nuclear accumulation of the p65 subunit of NF-κB, 
inhibition by the IKK inhibitor, BMS-345541, and histone the 
modification inhibitors, resminostat, entinostat or anacardic 
acid. Combined treatment with resveratrol and piceatannol 
also decreased tumor cell survival as indicated by the upregu-
lation of the DNA damaging marker, γH2AX, the cleavage 
of caspase 3, the downregulation of the survival markers, 
p38-MAPK/c-Myc, and G1-to-S cell cycle arrest.
Introduction
Programmed cell death ligand 1 (PD-L1) is a functional ligand 
of programmed cell death 1 (PD-1) (1). The binding of tumor 
cell PD-L1 to immune T-cell PD-1 inhibits T-cell activation 
and attenuates T-cell-mediated immunosuppression (2-4). This 
results in the evasion of host antitumor immunity, potentially 
reducing the efficacy of anticancer therapies and resulting in 
a poor clinical outcome (2,5,6). To counter the escape from 
the host immune surveillance system by tumor cells, blockade 
strategies using monoclonal antibodies (mAbs) to prevent 
the binding of PD-L1 to PD-1 have been developed (7-12). 
The clinical efficacy of this approach has been demon-
strated in certain cancer types, including melanoma (13-16), 
non-small-cell lung cancer (17-19) and renal carcinoma (20). 
Blockade therapy differs from tumoricidal chemotherapy in 
that its antitumorigenic effects involve boosting host immu-
nity concomitant with the modulation of the expression/
activity of the repertoire of cytotoxic T-cell and T-regulatory 
cells (21-24). Although success in anti-PD-1/PD-L1 therapy 
has made it possible to achieve tumor eradication and disease 
remission/cure, outstanding challenges remain. Only 31% of 
patients with advanced melanoma treated intravenously with 
anti-PD-1 drugs (nivolumab) have exhibited objective tumor 
regression (14). Likewise, the same therapeutic regimen has 
shown response rates ranging from 25% in renal cancer (20), 
to 19% in non-squamous non-small-cell lung cancer (17) and 
to 20% in squamous non-small-cell lung cancer (18), respec-
tively. Moreover, a positive therapeutic response typically 
occurs in patients with PD-L1-positive tumors (13,25).
Since the expression of PD-L1 in cancer cells may affect the 
patient response to immune blockade therapy, it is of interest to 
identify agents capable of modulating the expression of PD-L1. 
In this study, we focused on resveratrol, a stilbenoid present 
abundantly in red wine, red grape skin and peanuts (26,27). 
Interest in resveratrol stems largely from the report in 1997 by 
Jang et al, showing that the molecule prevents the development 
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of pre-neoplastic lesions in carcinogen-exposed mammary 
glands, and the inhibition of initiation and promotion of skin 
cancer in a mouse model (28). Since then, numerous studies 
have demonstrated its broad‑spectrum beneficial health effects, 
including, anti-inflammatory (29,30) and anticancer activi-
ties (26). Several mechanisms (31,32) and target proteins for 
the biological and pharmacological activities of resveratrol 
have been identified and characterized (33‑42). Resveratrol 
has also been reported to exert immunomodulatory effects, as 
illustrated by the induction of interferon (IFN)-γ expression in 
CD8+ T-cells both ex vivo and in vivo (43), and the inhibition 
of the proliferation of CD4+ T-cells (43,44). Craveiro et al (45) 
recently demonstrated that low-dose resveratrol (20 µM) acti-
vates human CD4+ cells and induces DNA damage response, 
while high-dose resveratrol (100 µM) induces G1 phase cell 
cycle arrest, suggesting that resveratrol may act on host immune 
cell types in a dose-dependent manner. The chemopreventive 
activity of resveratrol was first demonstrated using skin and 
breast cancer models (28), and recent clinical trials support the 
use of resveratrol in colorectal cancer (46,47). Thus, in this study, 
we selected breast and colorectal cancer cell lines to examine 
the regulatory effects of resveratrol and its biotransformed 
product, piceatannol, on the expression of PD-L1. The results 
revealed that both dietary stilbenoids, alone or in combination, 
copiously increased the expression level of PD-L1 in some 
breast and colorectal cancer cells via HDAC3/p300-mediated 
nuclear factor (NF)-κB signaling. In addition, both stilbenoids 
exerted cytotoxic effects on the tumor cells.
Materials and methods
Reagents. Resveratrol, piceatannol, resminostat, entinostat, 
mocetinostat, vorinostat, curcumin, garcinol, anacardic acid 
and Tip60i were purchased from Selleckchem (Houston, 
TX, USA). MB-3 and BMS-345541 were purchased from 
MilliporeSigma (Burlington, MA, USA). Pterostilbene and 
myricetin were from LKT Laboratories (St. Paul, MN, USA) 
and trimethoxy-resveratrol (trans-3,5,4'-trimethoxystilbene) 
was from Cayman Chemical Co. (Ann Arbor, MI, USA). 
Stock solutions of the chemicals were prepared based on the 
information provided by the manufacturer and maintained 
at ‑20˚C. The antibodies for human PD‑L1 (E1L3N, 13684), 
p38 MAPK (D13E1, 8690), NF-κB p65 (D14E12, 8242), 
γH2AX (20E3, 9718), cleaved caspase 3 (D3E9, 9579), IRF-1 
(D5E4, 8478) and rabbit IgG isotype monoclonal antibody 
(DA1E, 5742) conjugated to PE were obtained from Cell 
Signaling Technology (Beverly, MA, USA). c-Myc antibody 
(9E10, sc‑40) was obtained from Santa Cruz Biotechnology 
Inc. (Santa Cruz, CA, USA). Fetal bovine serum, RPMI‑1640, 
DMEM, streptomycin and penicillin were from Gibco/Thermo 
Fisher Scientific (Waltham, MA, USA). All other chemicals 
and solvents were of analytical grade.
Cell culture and treatment. Human BT549 (breast cancer), 
BT474 (invasive ductal carcinoma), SKBR3 (breast cancer), 
HCT116 (colon cancer), SW480 (colon cancer), HT29 (recto-
sigmoid adenocarcinoma) and SW620 (colon cancer) cells were 
obtained from the American Type Culture Collection (ATCC, 
Rockville, MD, USA). Human Cal51 (breast cancer) cells 
were from the Leibniz Institute DSMZ‑German Collection of 
Microorganisms and Cell Cultures (Braunschweig, Germany). 
The cells were maintained in RPMI-1640 or DMEM culture 
media supplemented with penicillin, streptomycin and 
10% heat-inactivated fetal bovine serum according to the 
manufacturer's instructions. The cells were split once a week 
and the media were changed every 3-4 days.
In all experiments described in this study, parent/parental 
or DMSO treated cells all refer to untreated, control cells. For 
treated cells, the conditions (dose and treatment duration) and 
whether any reagents were used together at specific doses were 
as indicated in the figure legends.
Immunohistochemistry. Paraffin-embedded SW620 colon 
cancer cells were immunohistochemically stained to evaluate 
the protein expression of PD-L1, c-Myc, p38 MAPK, γH2AX 
and cleaved caspase 3. Following deparaffinization and rehy-
dration, sections of SW620 cells were prepared. The slides 
were heated in the Retriever 2000 pressure cooker (Electron 
Microscopy Sciences, Hatfield, PA, USA) in Borg buffer pH 9.5 
(Biocare Medical, Concord, CA, USA) and cooled to room 
temperature. Endogenous peroxidase activity was inactivated 
with Peroxidazed 1 (Biocare Medical) for 10 min. Non‑specific 
protein interactions were blocked for 10 min with Background 
Punisher (Biocare Medical). The sections were incubated 
with the primary antibodies, indicated above, at a dilution of 
1/200 for 1 h, washed in TBS and incubated with SignalStain 
Boost IHC Detection Reagent (Cell Signaling Technology) 
for 30 min. Following washes in TBS, immunoreactivity was 
visualized by development with 3,3'‑diaminobenzidine (DAB+, 
Dako, Carpinteria, CA, USA) for 5 min. Immunostained 
sections were briefly counterstained with CAT hematoxylin, 
washed in tap water, dehydrated in a graded alcohol series, 
cleared in xylene and coverslipped with Permount mounting 
medium (Fisher Scientific Co. L.L.C., Pittsburgh, PA, USA).
Flow cytometric analysis for the surface expression of 
PD‑L1. The cells were harvested and fixed in 4% parafor-
maldehyde for 10 min. The cells were then rinsed twice with 
phosphate-buffered saline (PBS) before a 30-min staining 
was performed to prepare the samples for flow cytometry 
using a rabbit anti-human PD-L1 monoclonal antibody 
(E1L3N) conjugated to phycoerythrin (PE). As controls, cell 
samples were also stained for 30 min using rabbit IgG isotype 
monoclonal antibody (DA1E) conjugated to PE. Following 
labeling with antibody, the cells were rinsed twice with PBS 
and re-suspended with PBS. The data shown as the geometric 
means from n=3-4 independent experiments were acquired on 
a DB LSR Fortessa X‑20, and analyzed with FlowJo version 10 
software (BD Biosciences, San Jose, CA, USA).
PD‑L1 mRNA analyses using the Cancer Cell Line Encyclopedia 
(CCLE) database. The basal PD-L1 mRNA expression levels 
shown in Fig. 2B, presented as transcript per million (TPM) 
were obtained from a public Cancer Cell Line Encyclopedia 
(CCLE, https://portals.broadinstitute.org/ccle/home) database 
for cancer cell lines tested.
NF‑κB reporter assay. The A549-Dual cells purchased from 
InvivoGen (San Diego, CA, USA) were used. These are deriva-
tives of the A549 human lung carcinoma cells containing the 
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stable integration of two inducible reporter constructs. The 
constructs allow for the co-expression of a secreted embry-
onic alkaline phosphatase (SEAP) reporter gene under the 
control of the IFN-β minimal promoter fused 5 five NF‑κB 
binding sites, and, a Lucia luciferase gene encoding a secreted 
luciferase whose transcription is driven by an ISG54 promoter 
fused to 5 IFN-stimulated response elements. The cells were 
treated for the specified amount of time (8, 24 and 48 h) with 
resveratrol or piceatannol, each at 100 µM or combined, each 
at 50 µM (referred to as combo-100) to yield a concentration 
of 100 µM and the secreted alkaline phosphatase and Lucia 
luciferase in the supernatant of the control and treated cells 
were detected using the Quanti-Blue reagent from InvivoGen. 
The results were scored by the fluorescence intensity on 
a Perkin Elmer EnSpire set at a wavelength of 650 nm 
(PerkinElmer Inc., Shelton, CT, USA). To determine the role of 
NF-κB in mediating the induction of PD-L1, the IKK inhibitor, 
BMS-345541, was administered for 24 h in vitro prior to expo-
sure to the combination of piceatannol and resveratrol, each at 
50 µM to yield a concentration of 100 µM, for a further 48 h. 
BMS-345541 was added at increasing concentrations (1, 4 and 
8 µM), while the dose of the combination was kept constant.
Cell cycle/apoptosis analysis. The cells were harvested and 
washed with PBS then re-suspended in cold 1% formaldehyde 
in PBS solution for 15 min at 4˚C. The cells were washed 
twice in PBS and re-suspended in ice-cold 70% ethanol and 
stored at ‑20˚C for 2 h prior to analysis. Prior to fluorescence 
measurement the cells were stained with 4',6-diamidine-
2'-phenylindole dihydrochloride (DAPI). The intensity of blue 
fluorescence emission of DAPI stained DNA, excited with the 
UV laser (355 nm) was measured, recorded and analyzed on 
a MoFlo flow cytometer (Beckman Coulter Life Sciences, 
Indianapolis IN, USA) using Kaluza fluorescence intensity 
analysis software (48). Experiments were repeated and repre-
sentative data are presented.
Statistical analysis. All data are presented as the mean ± 
the standard error of the mean. A Student's t-test or two-way 
ANOVA with Bonferroni correction were performed to deter-
mine statistical significance between frequencies or mean 
fluorescence intensities of assessed cell populations using 
GraphPad Prism 6 (GraphPad Software). Statistical signifi-
cance of results was as indicated in each figure.
Results
PD‑L1 expression is increased by dietary stilbenoids, resvera‑
trol and/or piceatannol in breast and colorectal cancer cells. 
We first assessed any alterations in PD‑L1 levels using the Cal51 
breast cancer and HCT116 colon cancer cells treated with stil-
benoids, specifically, resveratrol, piceatannol, pterostilbene and 
3,5,4'‑trimethoxystilbene, for comparison with the flavonoid, 
myricetin (the chemical structures of the compounds are shown 
in Fig. 1A). The surface expression of PD-L1 in the control 
(DMSO-treated, also referred to as parent/parental cells) and 
treated Cal51 and HCT116 cells was assayed by flow cytometry. 
Resveratrol significantly increased the expression of PD‑L1 in 
the Cal51 cells, while treatment with piceatannol resulted in a 
marked increase in the PD-L1 level in HCT116 cells (Fig. 1B).
To determine whether the upregulation of PD-L1 by 
resveratrol and piceatannol was broadly or uniquely observed 
in specific breast or colon cancer cell lines, we assayed any 
alterations in PD-L1 expression using a panel of breast (Cal51, 
BT549, BT474 and SKBR3) and colorectal (HCT116, SW480, 
Figure 1. Effects of dietary polyphenols on programmed cell death ligand 1 
(PD-L1) expression in human breast and colon cancer cells. (A) Chemical 
structure of each of the polyphenols tested. (B) The Cal51 human breast 
cancer cell line and HCT116 colon cancer cell line, were cultured in vitro 
and treated with increasing concentrations of 5 polyphenols for 48 h, respec-
tively, namely resveratrol (Res), piceatannol (Pic), pterostilbene (PTS), 
trimethylstilbene (TriMRes) and myricetin. Following treatment, the cells 
were harvested and stained for the surface expression of PD‑L1 by flow 
cytometry. The geometric mean of mean fluorescent intensity (MFI) of 
phytoerythrin (PE) area was used as the readout of PD-L1. The levels of 
PD-L1 were converted to a bar graph to represent the respective changes in 
PD-L1 expression following treatment. The parental condition (also referred 
to as DMSO‑treated, or control cells). Statistical difference reflects the com-
parison of treated samples to the parental condition. The data shown were 
from n=3 independent experiments. *P<0.05.
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HT29 and SW620) cancer cell lines. In addition, we also 
determined whether the synergistic upregulation of PD-L1 
may result from treatment with the two stilbenoids. The differ-
ential increase in PD-L1 expression induced by resveratrol 
or piceatannol was observed in 2/4 breast and 3/4 colorectal 
cancer cell lines treated with either of the stilbenoids as a 
single agent (Fig. 2A). The combination of resveratrol and 
piceatannol acted synergistically; 50 µM each of resveratrol 
and piceatannol combined and referred to as ‘combo-100’ 
resulted in significantly greater induction of PD‑L1 expres-
sion; specifically, ≥4.5‑fold in the Cal51 and ≥3.5‑fold in the 
SW620 cells than 50 µM of either stilbenoid added alone 
(Fig. 2A). Gene expression analyses frequently reveal that the 
relative abundance of mRNA is only weakly or even inversely 
associated with the level of protein expression (49-51). Thus, 
in this study, to determine whether the differential expression 
level of endogenous PD-L1 mRNA might contribute to the 
observed induction of PD-L1 by resveratrol and piceatannol 
in these two cell lines, relative to the panel of the other studied 
cell lines with the same cancer type grouping, the basal PD-L1 
mRNA expression levels, shown as TPM were obtained from 
a public Cancer Cell Line Encyclopedia (CCLE, https://
portals.broadinstitute.org/ccle/home) database for cancer cell 
lines tested. In the breast cancer cell lines, the endogenous 
level of PD‑L1 mRNA ranked as follows: Cal51 ≤ BT474 
< SKBR3 ≤ BT549 (Fig. 2B); however, the induction of PD‑L1 
by co-treatment with resveratrol and piceatannol yielded the 
opposite result: Cal51 (~7‑fold) ≥ BT474 (~ 4‑fold) > SKBR3 
(~2‑fold) ≥ BT549 (~2‑fold) (Fig. 2A). A similar trend was also 
observed in the colorectal cancer cells; namely, the endogenous 
PD‑L1 mRNA ranking was as follows: SW620 ≤ HCT116 
< HT29 ≤ SW480 (Fig. 2B), whereas the relative induction of 
PD-L1 decreased from high to low as follows: SW620 (~4-fold) 
> HCT116 (~3‑fold) > SW480 (~3‑fold) > HT29 (~1.5‑fold) 
(Fig. 2A). These results suggest that tumors with a low endog-
enous mRNA level of PD-L1 are more likely to be affected by 
resveratrol and/or piceatannol, alone or in combination.
NF‑κB mediates the upregulation of PD‑L1 induced by 
resveratrol and/or piceatannol. IFN-γ is known to induce 
Figure 2. Effects of resveratrol and piceatannol on programmed cell death ligand 1 (PD-L1) expression in human breast and colon cancer cells. (A) A panel of 
4 breast (Cal51, BT549, BT474 and SKBR3) and colorectal (HCT116, SW480, HT29 and SW620) cancer cell lines were incubated with increasing concentra-
tions of resveratrol or piceatannol, as single agents or in combination for 48 h. Following treatment, the cells were harvested and stained and quantified for 
PD‑L1‑PE surface expression by flow cytometry. The induction of PD‑L1 expression was based on comparison to a DMSO‑treated sample (control used 
throughout all experiments), and to isotype control staining. The geometric mean of MFI of PE area was used as the PD-L1 readout. The levels of PD-L1 
from n=3 experiments were converted to a bar graph to represent the respective changes in PD-L1 expression following treatment. The parental condition 
represents the untreated control. The statistical difference reflects comparison of treated samples to parental condition. (B) RNA‑seq analysis of constitutive 
mRNA expression of PD-L1 in panel of breast and colon cancer cells. Basal PD-L1 mRNA levels, shown as transcript per million (TPM) were obtained from a 
public Cancer Cell Line Encyclopedia (CCLE) database and ranked from low to high according to the relative TPM expression by most of the breast and colon 
cancer cell lines tested in (A) https://portals.broadinstitute.org/ccle/home. The asterisks apply to comparisons made among treated samples: *P<0.05, **P<0.01, 
***P<0.001. In addition, the ‘x’ symbol refers to comparisons made between the untreated, control sample with the treated sample: xP<0.05 (treated vs. control).
INTERNATIONAL JOURNAL OF ONCOLOGY  53:  1469-1480,  2018 1473
PD-L1 expression by upregulating its transcription through 
the activation of interferon regulatory transcription factor 
(IRF-1) (52,53). Thus, in this study, we investigated whether 
the same mechanism may contribute to the resveratrol- 
and/or piceatannol-mediated induction of PD-L1 expression. 
The results of immunohistochemistry revealed no change in 
IRF-1 expression in the SW620 cells treated for 48 h with 
‘combo-100’ compared to the control (data not shown). Since 
the NF-κB consensus sequence is also present in the PD-L1 
gene promoter (52,53), and NF-κB plays a major role in the 
transcription of PD-L1 by IFN-γ (54-56), in this study, we 
examined whether the induction of PD-L1 by resveratrol and/or 
piceatannol was due to the activation of NF-κB. The A549 
cells co-expressing the SEAP reporter gene and Lucia lucif-
erase gene were used to investigate the association between 
NF-κB activity and the PD-L1 expression levels following 
treatment with the two stilbenoids, alone or combination. In 
this dual reporter assay, the secreted SEAP and Lucia lucif-
erase in the culture supernatant were separately measured to 
provide a quantitative readout of the transcriptional impact of 
NF-κB and the IFN signaling pathways. The time-dependent 
(≥24 h) and synergistic induction of NF‑κB expression 
induced by piceatannol alone and by combined treatment with 
resveratrol was observed (Fig. 3A). In response to stimuli, the 
Figure 3. Control of nuclear factor (NF)-κB-mediated programmed cell death ligand 1 (PD-L1) expression by resveratrol and piceatannol. (A) A549 dual 
reporter cells were used to assay the activation of NF-κB following treatment with resveratrol or piceatannol, each at 100 µM or combined, each at 50 µM 
(referred to as combo-100) to yield a concentration of 100 µM. Resveratrol as a single agent resulted in an optimal early time activation of NF-κB, while 
piceatannol alone decreased NF-κB signaling at 8 h and followed by a progressive increases at 24 and 48 h, respectively. When used in combination, the 
two stilbenoids led to a marked increase in NF-κB signaling over the tested duration of 48 h. The parental condition represents the untreated control. The 
data shown are from 1 experiment. (B) Immunohistochemistry of the subcellular localization of NF‑κB p65 subunit in SW620 colon cancer cells treated 
with a combination of piceatannol and resveratrol, each at 50 µM to yield a concentration of 100 µM vs. the untreated cells. The analysis showed that p65 
translocated from the cytoplasm to the nucleus by the combined use of the stilbenoids, indicating the activation of NF-κB signaling. Images were captured at 
x20 magnification and cropped to show the field of cells representative of the effect of treatment. The results are representative of 5 sections from 1 experiment. 
We did not quantify the percentage of cells in which translocation occurred in these samples. The parental condition represents the control. The image in the 
inset represents a high magnification image of the cells in the field of view. (C) BMS‑345541, an inhibitor of IKK, was administered for 24 h in vitro prior to 
exposure to the combination of piceatannol and resveratrol, each at 50 µM to yield a concentration of 100 µM, for a further 48 h. BMS-345541 was added at 
increasing concentrations (1, 4 and 8 µM) while the dose of the combination was kept constant. Following treatment, the cells were harvested and stained for 
PD‑L1 expression by flow cytometry. The geometric mean of the mean fluorescent intensity (MFI) of the phytoerythrin (PE) area was used as the readout for 
PD-L1 expression. The parental condition represents the untreated control. The results are representative of 3 experiments.
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inhibitory protein IκB is degraded, which leads to the release/
translocation of heterodimer p65/p50 from the cytoplasm to 
the nucleus (57,58). Therefore, the activation of NF-κB by the 
combined stilbenoids was examined in the SW620 cells by 
immunohistochemistry to analyze changes in the localization 
of p65; 48 h of exposure to ‘combo-100’ resulted in an increase 
in the translocation and nuclear accumulation of p65, as shown 
in Fig. 3B (inset).
The small molecule, BMS-345541, is an IKK kinase 
inhibitor (59) that prevents IκB phosphorylation, to effectively 
suppress the translocation of NF-κB into the nucleus for 
participation in transcriptional activation of NF-κB-responsive 
genes (57,58). Thus, in this study, we then examined whether 
the stilbenoid-induced PD-L1 expression can be blocked by 
BMS-345541. In SW620 cells, the induction of PD-L1 by 
‘combo-100’ was inhibited by 48% with 1 µM BMS-345541 
(Fig. 3C). Furthermore, a dose-dependent inhibition was 
observed with the 1, 4 and 8 µM of IKK inhibitor concentra-
tion range (Fig. 3C). These results, showing that the inhibition 
of IKK significantly decreased PD‑L1 expression in SW620 
cells suggest that NF-κB activation is involved in the induction 
of PD-L1 expression by resveratrol or piceatannol either alone, 
or in combination.
Histone deacetylase inhibitors (HDACis) and histone acet‑
yltransferase inhibitors (HATis) modulate the induction of 
PD‑L1 expression induced by the combination of resveratrol 
and piceatannol. The expression of PD-L1 can be regulated via 
histone acetylation/deacetylation (60,61) and resveratrol is an 
activator of HDAC (62). To investigate whether the induction 
of PD-L1 by the combination of resveratrol and piceatannol 
is blocked by inhibitors of HDAC or HAT, HDACis (vori-
nostat, mocetinostat, resminostat and entinostat) and HATis 
(curcumin, garcinol, anacardic acid, MB-3 and Tip60i) were 
used to assess their effects on the modulation of PD-L1 by 
the combined use of the stilbenoids. The cells were pre-treated 
for 48 h with individual HDACis/HATis alone or in combina-
tion with 60 µM of either of the stilbenoids, followed by the 
flow cytometric analysis of PD‑L1 expression. The addition 
of HDACis or HATis alone did not affect PD-L1 expression 
compared to the untreated controls (Fig. 4). When the SW620 
cells were pre‑treated with histone modification inhibitors, 
Figure 4. Effects of histone deacetylase inhibitors (HDACis) and histone acetyltransferase inhibitors (HATis) on the induction of programmed cell death 
ligand 1 (PD-L1) expression. (A) The SW620 colon cancer cell line was treated in vitro with different classes of HDACis at various concentrations for 72 h. 
Following treatment, the cells were harvested and stained for PD‑L1 expression by flow cytometry. The results were quantified using the geometric mean of 
the mean fluorescent intensity (MFI) of the phytoerythrin (PE) area as the readout for the expression of PD‑L1. (B) The same cancer cell line, SW620, was 
treated with a known class of HATis listed, for 72 h and PD‑L1 expression was analyzed and quantified. ‘Combo’ indicates treatment with both resveratrol and 
piceatannol each at 60 µM for 48 h. The parental condition represents the untreated control. The data shown are from 1 experiment.
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the ability of the stilbenoids to induce PD-L1 was markedly 
reduced by two HDACis (5 µM of resminostat and entinostat) 
and also by the HATi, anacardic acid (1 µM) (Fig. 5). These 
results demonstrated that histone modification inhibitors can 
suppress the induction of PD-L1 expression by stilbenoids. The 
data are consistent with the interpretation that the upregulation 
of PD-L1 by stilbenoids involves transcriptional control.
Induction of apoptotic and cell cycle changes by the combined 
use of resveratrol and piceatannol. The upregulation of PD-L1 
may allow cancers to evade the host immune system and 
acquire resistance to anticancer drugs. Having demonstrated 
that the upregulation of PD-L1 expression by stilbenoids in 
the SW620 colon cancer cells, we then investigated whether 
stilbenoids affect the survival status of cells by analyzing two 
biomarkers related to apoptosis, namely, the expression of the 
DNA damage indicator γH2AX, and that of cleaved caspase 3. 
In addition, markers associated with cell survival, p38-MAPK 
and c-Myc, were also assessed using immunohistochemistry. 
Treatment of the SW620 cells for 48 h with ‘combo-100’ resve-
ratrol and piceatannol increased the expression of γH2AX and 
that of cleaved caspase 3, and downregulated the p38-MAPK 
and c-Myc levels (Fig. 6A). The induction of γH2AX is charac-
teristic of DNA fragmentation and damage during apoptosis, 
and thus supports the interpretation that exposure to resvera-
trol and/or piceatannol causes DNA damage and apoptosis via 
the activation of caspase 3. We then assessed whether treat-
ment with the stilbenoids altered cell cycle distribution by flow 
cytometric analysis. An increase in the percentage of cells in 
the S phase of the cell cycle, from 19 to ~30%, a distinct reduc-
tion in the proportion of G1 phase cells (from 66 to ~30%), 
and a marked decrease in the percentage of G2M phase cells, 
from 12 to ~3% were observed. There was also an increase in 
the percentage of cells with fractional DNA content (‘sub-G1 
cells’), an indication of apoptosis from 2.85% in the control 
cells to 31.84, 35.08 and 36.55% in the cells treated with 
Figure 5. Effects of histone deacetylase inhibitors (HDACis) and histone acetyltransferase inhibitors (HATis) on the induction of programmed cell death 
ligand 1 (PD-L1) expression by a combination of resveratrol and piceatannol. (A) The SW620 colon cancer cell line was treated in vitro with increasing con-
centrations of HDACis for 24 h prior to exposure to a combination of resveratrol and piceatannol, each at 60 µM, for an additional 48 h. Following treatment, 
the cells were harvested and stained for PD‑L1 expression by flow cytometry. The geometric mean of the mean fluorescent intensity (MFI) of the phytoerythrin 
(PE) area was used as the readout for PD‑L1 expression. The high dose of entinostat and resminostat significantly reduced expression of PD‑L1. (B) The SW620 
cells were treated with listed HATis, for 24 h prior to exposure to the combined treatment as described in Fig. 3A. The analysis and quantification of PD‑L1 
were identical to those shown in Fig. 3A. ‘Combo’ indicates treatment with both resveratrol and piceatannol each at 60 µM for 48 h. The parental condition 
represents the untreated control.
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Figure 6. Effects of resveratrol and/or piceatannol on the cell survival and cell cycle status. (A) Immunohistochemical staining of SW620 parental cells, top 
row, and cells treated with the combination of resveratrol and piceatannol, each at a concentration of 50 µM, are shown on the bottom row. Cells from both 
conditions were stained with antibodies against γH2AX, cleaved caspase 3, p38 MAPK and c-Myc, as described in the Materials and methods. Images were 
captured at x20 magnification and cropped to show the field of cells representative of the effect of treatment. (B) Flow cytometric analysis of the changes on 
cell cycle status and apoptotic index of SW620 cells. The percentage of cells in particular phases of the cell cycle identified by their DNA content is indicated. 
The data are shown from a single representative experiment.
Figure 7. Flow cytometric analysis of the changes in cell cycle status and the apoptotic index of Cal51 and SW620 cells. (A) Untreated cells. (B) Cells treated 
with 10 µM resveratrol, 48 h. (C) Cells treated with 10 µM piceatannol, 48 h. (D) Cells treated with 10 µM of resveratrol plus 10 µM piceatannol, 48 h. The 
percentage of apoptotic cells (Ap) identified by fractional DNA content, sub‑G1 cells is shown in each panel (thick arrows). The percentage of cells in particular 
phases of the cell cycle identified by their DNA content, are as shown by the thin arrows in the top panel (Ca151 cells) and the bottom panel (SW620 cells). The 
data shown are representative of two experiments.
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50 µM resveratrol, 50 µM piceatannol or 50 µM of these two 
compounds for 48 h, respectively (Fig. 6B). We also examined 
and determined that low-dose (10 µM) resveratrol and/or 
piceatannol did not induce PD-L1 expression, whereas the 
analysis of cell cycle phase distribution changes using Cal51 
and SW620 cell cultures treated for 48 h revealed an apparent 
increase in the proportion of S-phase cells concomitant with 
the reduction of G2M-phase cells in cultures treated with 
resveratrol alone, and to an even greater extent following 
treatment with both stilbenoids (Fig. 7). In addition, the 
combination of resveratrol and piceatannol induced apoptosis 
in both cell types to a much greater degree than each of them 
alone, as demonstrated by an increase in the percentage of 
cells with fractional DNA content (‘sub-G1 cells’), an indica-
tion of apoptosis (compare Fig. 7A with Fig. 7B-D) (48,63,64). 
Taken together, our findings indicate that stilbenoids not only 
increase PD-L1 expression, but may also induce DNA damage, 
leading to increased cell death in tumor cells, such as SW620 
colon cancer cells.
Discussion
An association has been observed between a decrease in T-cell 
proliferation and an increase in apoptosis and tumor immune 
evasion, with an increase in the expression of T-cell inhibitory 
protein PD-L1 on cancer cells (2,3), providing the impetus for 
understanding the control of PD-L1 expression using cancer 
cells as a model. In this study, we examined the hypothesis that 
dietary stilbenoids may act as modulators of PD-L1 expres-
sion in tumor cells. We focused on the effects of resveratrol, 
a grape-derived polyphenol that has shown chemopreventive 
effects in various cancer types (33-42), and its hydroxylated 
derivative, piceatannol. Questions raised and addressed in 
this study included whether: i) Structurally‑modified stilben-
oids have the same ability to modulate PD-L1 expression; 
ii) the effects of stilbenoids on PD-L1 expression can apply 
to different cancer types; iii) signaling pathways that control 
the stilbenoid-induced PD-L1 expression are effected; and 
iv) histone modification inhibitors (HDACis and HATis) block 
stilbenoid-induced PD-L1 expression.
Stilbenoids in general exert beneficial effects on human 
health (65). It has been reported that the 4'-hydroxy group of 
resveratrol is essential for its bioactivity (66). In this study, we 
used breast and colorectal cancer cells to compare the modulatory 
effects of stilbenoids on PD-L1 expression, namely, piceatannol 
(3',4',3,5-trans-trihydroxystilbene), 3,5,4'-trimethoxystilbene, 
and pterostilbene (3,5-dimethoxy-4'-hydroxy-E-stilbene), with 
resveratrol (3,5,4'-trans-trihydroxystilbene) and myricetin, a 
naturally occurring flavonoid present in abundance in edible 
foods (67). The results presented in Figs. 1 and 2 demonstrate 
that the hydroxyl, but not methoxy groups on stilbenoids are 
important for the induction of PD-L1. However, no increase in 
PD-L1 expression was evident in the cells treated with myricetin 
(3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone), 
a flavonoid that contains 6 hydroxyl groups (Fig. 1). These 
results suggest that the 3,5-dihydroxy-trans-stilbene structure 
is required for the induction of PD-L1 in the cells used.
The expression level PD‑L1 of was significantly increased 
in the breast and colon cancer cells treated with resveratrol 
and piceatannol, both as a single agent and when used in 
combination (Figs. 1 and 2). Moreover, PD-L1 expression 
was synergistically upregulated 4.5-fold in the Cal51 breast 
cancer and ≥3.5‑fold in the SW620 colon cancer cells by the 
combined use of resveratrol and piceatannol (Fig. 2A). Of note, 
both cancer cells express low basal levels of PD-L1 mRNA 
expression (Fig. 2B). Since, as noted, a positive response and 
improved clinical outcome to anti-PD-L1 blockade therapy are 
best observed in patients with PD-L1-positive tumors (presum-
ably reflecting a high expression of PD‑L1), we surmise that 
agents capable of upregulating PD-L1 expression in tumor 
cells expressing low PD‑L1 can sensitize such cancer cells for 
an improved response to PD-L1 blockade. As a corollary, we 
also hypothesized that the combined use of resveratrol and 
piceatannol co-administered with anti-PD-L1 immunotherapy 
may exhibit clinical benefits in cancer patients with no‑or‑
low‑PD‑L1 tumors. Whether the efficacy to PD‑L1 blockade 
may be enhanced by the combined intake of resveratrol and/
or piceatannol, concomitantly or sequentially, remains to be 
verified.
This study also provides evidence showing that the resvera-
trol- and piceatannol-mediated upregulation of PD-L1 requires 
the activation of NF-κB (Fig. 3). In the SW620 cells, we showed 
that the induction of PD-L1 expression induced by resveratrol/
piceatannol was attenuated by the IKK inhibitor, BMS 345541 
(Fig. 3C). It has been previously demonstrated that the dura-
tion and function of nuclear NF-κB is regulated by reversible 
acetylation/deacetylation (68), and that NF-κB transcriptional 
response is controlled by the HDAC3-mediated deacetylation 
of RelA acting as an intranuclear molecular switch for turning 
‘on-off’ the NF-κB response (68); we therefore examined 
whether histone modification inhibitors affect the resveratrol/
piceatannol-mediated transcriptional control of PD-L1. Our 
findings revealed that two HDACis (e.g., resminostat and 
entinostat) and one HATi, anacardic acid, effectively blocked 
the induction of PD-L1 expression by resveratrol/piceatannol 
(Fig. 5). Both resminostat and entinostat are HDAC3 inhibi-
tors, thus lending support that the HDAC3-mediated NF-κB 
response plays a role in resveratrol/piceatannol-induced PD-L1 
expression. The suppression of PD-L1 induction by resveratrol 
using anacardic acid is in accordance with the described effect 
of anacardic acid as a HATi for p300 and p300/CBP and data 
reporting that resveratrol is a p300 activator (69,70). These 
results indicate that the expression of PD-L1 is regulated by 
the mechanism of histone acetylation/deacetylation and that 
resveratrol/piceatannol induces PD-L1 expression through 
HDAC3/p300-mediated NF-κB control.
It should be mentioned that the upregulation of PD-L1 
by resveratrol or piceatannol occur at doses not achievable 
physiologically and may exceed pharmacologically relevant 
concentrations (26,71). Conceivably, the effective dose could 
also be modulated by factors present locally at the site of 
responsive cells/tumors (e.g., different hormones, cytokines, 
products of cell metabolism or variable oxygen tension) 
and thus may additionally affect sensitivity of PD-1/PD-L1 
checkpoint to these compounds, perhaps amplifying their 
potential anticancer effect. It should also be noted that the 
doses used in the present experiments were based on titration 
studies (data not shown), and that the effectiveness of single or 
combined agents on the induction of PD-L1 in each cell line 
is above IC50. It would be of interest to determine what might 
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account for the variations observed in dosage dependence in 
different cell lines. Since the induction of PD-L1 expression by 
resveratrol and piceatannol are mediated through the NF-κB 
signaling pathway; the different dose-dependent responses 
and the upregulation of PD-L1 by resveratrol and piceatannol 
may be due to the variation in the endogenous level of NF-κB 
components, vis-à-vis, NF-κB1 (p105), NF-κB2 (p65), CHUK 
(IKK-α), IKBKB (IKK-β) and IKBKG (IKK-γ), in each of the 
cell lines tested. In RNA-seq analyses, we found that Cal51 
and SW620, both with a low endogenous level of PD-L1 
expression, expressed high levels NF-κB2 (p65) and CHUK 
(IKK-α) compared to cancer cell lines from same anatomical 
origin showing high PD-L1 expression (data not shown). 
Thus, it is tempting to propose that response in the induction 
of PD-L1 by stilbenoids in different cell lines from identical 
cancer types may be attributed to the level of expression of 
NF-κB2 (p65) and CHUK (IKK-α). Currently, experiments 
are underway to further test and confirm our hypothesis.
Another result of note in this study is that the SW620 
cells exposed to a high dose of both stilbenoids were partially 
restricted in cell cycle transition in the G2/M phase and display 
evidence of apoptosis (Fig. 6). Furthermore, the accumulation 
of cells in the S phase of the cell cycle may also be associated 
with an increase in their expression of PD-L1. This suggests 
that resveratrol and piceatannol affect cancer cells by a dual 
mechanism: i) The induction of PD‑L1 that sensitizes tumor 
cells for recognition by anti-PD-L1 antibodies; an effect that 
could diminish cancer cell evasion from immune surveil-
lance; and ii) the direct induction of cell cycle arrest, increase 
in DNA damage and cancer cell destruction via induction of 
apoptosis.
Since cancer patients expressing tumors positive for PD-L1, 
a negative T‑cell regulatory molecule, demonstrate efficacy 
to anti-PD-L1 blockade therapy with an improved clinical 
outcome, one might surmise that low PD-L1-expressing tumors 
may be sensitized and may display an improved responsive-
ness to PD-L1 blockade therapy using dietary agents. The cell 
culture experiments used in this study may be considered as a 
model for testing whether the sensitivity and responsiveness of 
tumor cells to PD-L1 targeted therapy can be augmented by 
priming with or co-exposure to stilbenoids, such as resveratrol 
and/or piceatannol. The hypothesis raised is as follows: The 
upregulation of membrane-associated PD-L1 in low PD-L1-
expressing tumor cells is a ‘find‑me’ approach for targeting by 
immune checkpoint inhibitors to potentially improve the effi-
cacy of anti-PD-L1 blockade therapy via stilbenoids. Indeed, 
we believe that the elevation of PD-L1 expression, as we have 
demonstrated in this study using pharmacological doses of 
the stilbenoids, resveratrol and piceatannol, may underlie the 
unresolved challenge in that the positive response to immune 
checkpoint blockade therapy in 19-31% of treated individuals 
is a limited to number of clinical indications, typically in 
patients whose tumors express elevated-PD-L1, which we 
stated explicitly in the Introduction. Thus, while on teleological 
grounds, the upregulation of PD-L1 by polyphenols in cancer 
could promote disease progression, we offer the consideration 
that the observed stilbenoid-induced PD-L1 increase be viewed 
from the hypothesis that agents capable of upregulating PD-L1 
expression in tumor cells could sensitize cancer cells for an 
improved clinical response to PD-L1 immune checkpoint 
blockade therapy. Testing these aspects would constitute a 
novel approach to confirm our hypothesis. These possibilities 
are under further investigative considerations in our labora-
tory. Studies are also planned to explore whether stilbenoids 
may impact host immune response, for example, by affecting 
PD-1 expression in PD-1-expressing Jurkat T-cells.
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